Sintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review
Immune checkpoint inhibitors (ICIs) have emerged as a powerful and efficacious therapeutic approach for many cancer patients. Sintilimab is a fully human IgG4 monoclonal antibody that binds with programmed cell death receptor-1 (PD-1) to block its interaction with ligands, thereby enhancing the anti...
Main Authors: | Xin Liu, Ziyue Zeng, Jianlei Cao, Xianqing Li, Muheremu Muhetaer, Zhili Jin, Huanhuan Cai, Zhibing Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-10-01
|
Series: | Journal of Cardiovascular Development and Disease |
Subjects: | |
Online Access: | https://www.mdpi.com/2308-3425/10/10/422 |
Similar Items
-
Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
by: Le Zhang, et al.
Published: (2023-03-01) -
A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma
by: Siming Zheng, et al.
Published: (2023-06-01) -
Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
by: Lingfang Tu, et al.
Published: (2021-12-01) -
Immune myocarditis related to sintilimab treatment in a patient with advanced lung adenocarcinoma: A case report
by: Yunling Lin, et al.
Published: (2022-10-01) -
Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review
by: Zhang L, et al.
Published: (2023-02-01)